Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18432732 | 1.00 | PPM1B (0.37) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL18120296 | 0.89 | CYP2C19 (0.33) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL18461227 | 0.89 | CYP2C19 (0.33) | SLC6A4SLC6A3SLC6A2CYP2C19 | |
| SCHEMBL19115141 | 0.89 | CYP2C19 (0.33) | SLC6A4SLC6A3SLC6A2CYP2C19 | |
| SCHEMBL12762662 | 0.88 | CYP2C19 (0.35) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL18117662 | 0.88 | CYP2C19 (0.35) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL12415463 | 0.88 | CYP19A1 (0.36) | SLC6A4SLC6A3SLC6A2CYP2C19 | |
| SCHEMBL12415472 | 0.82 | SLC6A3 (0.34) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL26347053 | 0.79 | PPM1B (0.43) | PPM1BPTPN1PPP1CCCYP2C19 | |
| SCHEMBL18118605 | 0.79 | ALDH1A1 (0.46) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197184-A1 | HYDROPHILICALLY MODIFIED FLUORINATED MEMBRANE (I) | PALL CORPORATION (US) | 2017-07-13 | — | — | US | disclosed |
| US-9643131-B2 | Hydrophilic porous polytetrafluoroethylene membrane (I) | PALL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643131-B2 | Hydrophilic porous polytetrafluoroethylene membrane (I) | PALL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9636641-B2 | Hydrophilically modified fluorinated membrane (I) | PALL CORPORATION (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636641-B2 | Hydrophilically modified fluorinated membrane (I) | PALL CORPORATION (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170028363-A1 | HYDROPHILIC POROUS POLYTETRAFLUOROETHYLENE MEMBRANE (I) | PALL CORPORATION (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170028363-A1 | HYDROPHILIC POROUS POLYTETRAFLUOROETHYLENE MEMBRANE (I) | PALL CORPORATION (US) | 2017-02-02 | — | — | US | disclosed |
| EP-3124100-A1 | HYDROPHILIC POROUS POLYTETRAFLUOROETHYLENE MEMBRANE | Pall Corporation (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160288061-A1 | HYDROPHILICALLY MODIFIED FLUORINATED MEMBRANE (I) | PALL CORPORATION (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3075765-A1 | HYDROPHILICALLY MODIFIED FLUORINATED MEMBRANE | Pall Corporation (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | PPM1B 2985/4885PTPN1 3461/4885PPP1CC 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.